Underberg - Figure 12 - Mortality Reduction in Subjects With Homozygous FH Correlates with Advances in Lipid-Lowering Therapy
Finally, more recent data from Circulation at the end of 2011 confirm again that survival probability, based on both major adverse cardiovascular events (MACE, top panel) and death (bottom panel), increases in patients on lipid therapy. Although this was another observational study, the results confirm again that lipid lowering therapy dramatically improves outcomes in patients with FH.
Underberg
J Clin Lipidol.
2012;